A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 14 Dec 2018
At a glance
- Drugs Tralokinumab (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms ECZTRA 3
- Sponsors LEO Pharma
- 05 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 16 Jul 2018 Planned primary completion date changed from 19 Jan 2019 to 1 Jan 2019.
- 16 Jul 2018 Planned End Date changed from 31 Aug 2019 to 30 Sep 2019.